Unlock stock picks and a broker-level newsfeed that powers Wall Street.
High Growth Tech Stocks in the US Market

In This Article:

The United States market has remained flat over the past week but has shown an 8.5% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in capturing emerging opportunities within this dynamic sector.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.44%

29.79%

★★★★★★

TG Therapeutics

26.18%

37.61%

★★★★★★

Alkami Technology

20.02%

85.16%

★★★★★★

Travere Therapeutics

28.43%

65.01%

★★★★★★

AVITA Medical

27.91%

55.77%

★★★★★★

TKO Group Holdings

22.48%

25.17%

★★★★★★

Clene

60.86%

63.07%

★★★★★★

Alnylam Pharmaceuticals

22.76%

58.40%

★★★★★★

Lumentum Holdings

21.55%

119.67%

★★★★★★

Ascendis Pharma

32.36%

59.79%

★★★★★★

Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Gilead Sciences

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs globally with a market cap of $134.36 billion.

Operations: Gilead generates revenue primarily from the discovery, development, and commercialization of innovative medicines, amounting to $28.75 billion. The company operates in the United States, Europe, and internationally.

Gilead Sciences has demonstrated resilience and innovation, particularly in its HIV treatment and prevention segments. With a recent executive change, appointing Diane E. Wilfong as interim Corporate Controller, the company remains stable in leadership transitions. At the Conference on Retroviruses and Opportunistic Infections (CROI 2025), Gilead presented promising data from its ALLIANCE trial showing Biktarvy's efficacy in HIV/HBV co-infection with high virologic suppression rates of 95.4% for HIV-1. Additionally, lenacapavir continues to show potential as a long-acting PrEP solution with ongoing Phase 1 studies indicating effective plasma concentrations for over a year post-administration, reinforcing Gilead's commitment to addressing global health challenges through groundbreaking R&D efforts focused on multi-stage mechanisms of action in antiviral treatments.

NasdaqGS:GILD Earnings and Revenue Growth as at Mar 2025
NasdaqGS:GILD Earnings and Revenue Growth as at Mar 2025

nCino

Simply Wall St Growth Rating: ★★★★☆☆